Dexamethasone and adrenocorticotropin suppress prolactin secretion in humans

E. Hubina, G. M. Nagy, B. Tóth, G. Iván, Z. Görömbey, I. Szabolcs, L. Kovács, M. Góth

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

It has been demonstrated that the regulatory pathways mediating basal and/or stimulus-induced prolactin (PRL) release in mammals are highly sensitive to adrenal corticoid inhibitory influence. We have investigated the effect of four different doses of dexamethasone (DEX) and the effect of adrenocorticotropin on PRL secretion in 197 patients (169 female, 28 male; age: 18-66 yr) with suspected hypercortisolemia - but only those with a normal glucocorticoid suppression test were involved in the study - and in 66 female patients (age: 18-39 yr) with suspected adrenocorticotropin-dependent hyperandrogenism. Overnight (1 mg), low-dose (0.5 mg every 6 h for 2 d), high-dose (2 mg every 6 h for 2 d), and long-lasting administration of DEX (0.5 mg every 6 h for 5 d) resulted in a significant decrease in PRL levels compared to the baseline. Similarly, a reduction in PRL levels could be detected following injection of adrenocorticotropin (250 μg). In hyperprolactinemic patients, the DEX-induced increase in PRL (ΔPRL, expressed in percentage of baseline) was significantly larger compared with normoprolactinemic subjects in all groups except those who received high-dose DEX) or adrenocorticotropin. These data clearly indicate that the secretory function of PRL cells in humans is sensitive to changes in the activity of the hypothalamo-pituitary-adrenal axis in a dose-dependent manner.

Original languageEnglish
Pages (from-to)215-219
Number of pages5
JournalEndocrine
Volume18
Issue number3
DOIs
Publication statusPublished - Aug 2002

Fingerprint

Prolactin
Adrenocorticotropic Hormone
Dexamethasone
Hyperandrogenism
Glucocorticoids
Mammals
Adrenal Cortex Hormones
Injections

Keywords

  • Adrenal corticoid
  • Adrenocorticotropin
  • Dexamethasone
  • Prolactin

ASJC Scopus subject areas

  • Endocrinology

Cite this

Dexamethasone and adrenocorticotropin suppress prolactin secretion in humans. / Hubina, E.; Nagy, G. M.; Tóth, B.; Iván, G.; Görömbey, Z.; Szabolcs, I.; Kovács, L.; Góth, M.

In: Endocrine, Vol. 18, No. 3, 08.2002, p. 215-219.

Research output: Contribution to journalArticle

Hubina, E. ; Nagy, G. M. ; Tóth, B. ; Iván, G. ; Görömbey, Z. ; Szabolcs, I. ; Kovács, L. ; Góth, M. / Dexamethasone and adrenocorticotropin suppress prolactin secretion in humans. In: Endocrine. 2002 ; Vol. 18, No. 3. pp. 215-219.
@article{65bffdb7ee8d4c6aaf6c3be384599670,
title = "Dexamethasone and adrenocorticotropin suppress prolactin secretion in humans",
abstract = "It has been demonstrated that the regulatory pathways mediating basal and/or stimulus-induced prolactin (PRL) release in mammals are highly sensitive to adrenal corticoid inhibitory influence. We have investigated the effect of four different doses of dexamethasone (DEX) and the effect of adrenocorticotropin on PRL secretion in 197 patients (169 female, 28 male; age: 18-66 yr) with suspected hypercortisolemia - but only those with a normal glucocorticoid suppression test were involved in the study - and in 66 female patients (age: 18-39 yr) with suspected adrenocorticotropin-dependent hyperandrogenism. Overnight (1 mg), low-dose (0.5 mg every 6 h for 2 d), high-dose (2 mg every 6 h for 2 d), and long-lasting administration of DEX (0.5 mg every 6 h for 5 d) resulted in a significant decrease in PRL levels compared to the baseline. Similarly, a reduction in PRL levels could be detected following injection of adrenocorticotropin (250 μg). In hyperprolactinemic patients, the DEX-induced increase in PRL (ΔPRL, expressed in percentage of baseline) was significantly larger compared with normoprolactinemic subjects in all groups except those who received high-dose DEX) or adrenocorticotropin. These data clearly indicate that the secretory function of PRL cells in humans is sensitive to changes in the activity of the hypothalamo-pituitary-adrenal axis in a dose-dependent manner.",
keywords = "Adrenal corticoid, Adrenocorticotropin, Dexamethasone, Prolactin",
author = "E. Hubina and Nagy, {G. M.} and B. T{\'o}th and G. Iv{\'a}n and Z. G{\"o}r{\"o}mbey and I. Szabolcs and L. Kov{\'a}cs and M. G{\'o}th",
year = "2002",
month = "8",
doi = "10.1385/ENDO:18:3:215",
language = "English",
volume = "18",
pages = "215--219",
journal = "Endocrine",
issn = "1355-008X",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - Dexamethasone and adrenocorticotropin suppress prolactin secretion in humans

AU - Hubina, E.

AU - Nagy, G. M.

AU - Tóth, B.

AU - Iván, G.

AU - Görömbey, Z.

AU - Szabolcs, I.

AU - Kovács, L.

AU - Góth, M.

PY - 2002/8

Y1 - 2002/8

N2 - It has been demonstrated that the regulatory pathways mediating basal and/or stimulus-induced prolactin (PRL) release in mammals are highly sensitive to adrenal corticoid inhibitory influence. We have investigated the effect of four different doses of dexamethasone (DEX) and the effect of adrenocorticotropin on PRL secretion in 197 patients (169 female, 28 male; age: 18-66 yr) with suspected hypercortisolemia - but only those with a normal glucocorticoid suppression test were involved in the study - and in 66 female patients (age: 18-39 yr) with suspected adrenocorticotropin-dependent hyperandrogenism. Overnight (1 mg), low-dose (0.5 mg every 6 h for 2 d), high-dose (2 mg every 6 h for 2 d), and long-lasting administration of DEX (0.5 mg every 6 h for 5 d) resulted in a significant decrease in PRL levels compared to the baseline. Similarly, a reduction in PRL levels could be detected following injection of adrenocorticotropin (250 μg). In hyperprolactinemic patients, the DEX-induced increase in PRL (ΔPRL, expressed in percentage of baseline) was significantly larger compared with normoprolactinemic subjects in all groups except those who received high-dose DEX) or adrenocorticotropin. These data clearly indicate that the secretory function of PRL cells in humans is sensitive to changes in the activity of the hypothalamo-pituitary-adrenal axis in a dose-dependent manner.

AB - It has been demonstrated that the regulatory pathways mediating basal and/or stimulus-induced prolactin (PRL) release in mammals are highly sensitive to adrenal corticoid inhibitory influence. We have investigated the effect of four different doses of dexamethasone (DEX) and the effect of adrenocorticotropin on PRL secretion in 197 patients (169 female, 28 male; age: 18-66 yr) with suspected hypercortisolemia - but only those with a normal glucocorticoid suppression test were involved in the study - and in 66 female patients (age: 18-39 yr) with suspected adrenocorticotropin-dependent hyperandrogenism. Overnight (1 mg), low-dose (0.5 mg every 6 h for 2 d), high-dose (2 mg every 6 h for 2 d), and long-lasting administration of DEX (0.5 mg every 6 h for 5 d) resulted in a significant decrease in PRL levels compared to the baseline. Similarly, a reduction in PRL levels could be detected following injection of adrenocorticotropin (250 μg). In hyperprolactinemic patients, the DEX-induced increase in PRL (ΔPRL, expressed in percentage of baseline) was significantly larger compared with normoprolactinemic subjects in all groups except those who received high-dose DEX) or adrenocorticotropin. These data clearly indicate that the secretory function of PRL cells in humans is sensitive to changes in the activity of the hypothalamo-pituitary-adrenal axis in a dose-dependent manner.

KW - Adrenal corticoid

KW - Adrenocorticotropin

KW - Dexamethasone

KW - Prolactin

UR - http://www.scopus.com/inward/record.url?scp=0036669132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036669132&partnerID=8YFLogxK

U2 - 10.1385/ENDO:18:3:215

DO - 10.1385/ENDO:18:3:215

M3 - Article

C2 - 12450312

AN - SCOPUS:0036669132

VL - 18

SP - 215

EP - 219

JO - Endocrine

JF - Endocrine

SN - 1355-008X

IS - 3

ER -